<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>American Society for Apheresis 2023 indications for therapeutic apheresis and cytapheresis procedures</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">American Society for Apheresis 2023 indications for therapeutic apheresis and cytapheresis procedures</h1>
<div class="graphic"><div class="figure"><div class="ttl">American Society for Apheresis 2023 indications for therapeutic apheresis and cytapheresis procedures</div><div class="cntnt"><table cellspacing="0"><colgroup width="64%"></colgroup> <colgroup span="3" width="12%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Indication</td> <td class="subtitle1_left">Modality</td> <td class="subtitle1_left">Category</td> <td class="subtitle1_left">Evidence</td> </tr> <tr> <td class="indent1">Acute disseminated encephalomyelitis (ADEM): Steroid refractory</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1">Acute fatty liver of pregnancy</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" rowspan="2">Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome): Primary treatment</td> <td>TPE</td> <td>I</td> <td>1A</td> </tr> <tr> <td>IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent1" rowspan="2">Acute liver failure</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td>TPE-HV</td> <td>I</td> <td>1A</td> </tr> <tr> <td class="indent1">Age-related macular degeneration, dry, high-risk</td> <td>DFPP</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1">Alzheimer disease, mild or moderate</td> <td>TPE</td> <td>III</td> <td>2A</td> </tr> <tr> <td class="indent1">Amyloidosis, systemic, dialysis-related</td> <td>Beta2 microglobulin adsorption</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">Anti-glomerular basement membrane disease (Goodpasture syndrome)</td> </tr> <tr> <td class="indent2"> <ul> <li>Diffuse alveolar hemorrhage (DAH)</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Dialysis-independence</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Dialysis-dependence, no DAH</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1">Atopic dermatitis (atopic eczema), recalcitrant</td> <td>ECP/IA/TPE/DFPP</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1">Autoimmune dysautonomia</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Autoimmune hemolytic anemia (AIHA), severe</td> </tr> <tr> <td class="indent2"> <ul> <li>Severe cold agglutinin disease</li> </ul> </td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Severe warm AIHA</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Babesiosis, severe</td> <td>RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Burn shock resuscitation</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1">Cardiac neonatal lupus</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Catastrophic antiphospholipid syndrome (CAPS)</td> <td>TPE</td> <td>I</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Chronic acquired demyelinating polyneuropathies</td> </tr> <tr> <td class="indent2"> <ul> <li>IgG/IgA/IgM related</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Anti-myelin-associated glycoprotein</li> </ul> </td> <td>TPE</td> <td>III</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins, and disialosyl antibodies (CANOMAD)/Chronic ataxic neuropathy with disialosyl antibodies syndrome (CANDA)</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Chronic focal encephalitis (Rasmussen encephalitis)</td> <td>TPE/IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)</td> <td>TPE/IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent1" rowspan="2">Coagulation factor deficiency and inhibitors</td> <td>IA</td> <td>III</td> <td>2B</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Complex regional pain syndrome, chronic</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" rowspan="2">Cryoglobulinemia, severe/symptomatic</td> <td>TPE/DFPP</td> <td>II</td> <td>2A</td> </tr> <tr> <td>IA</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">Cutaneous T cell lymphoma (CTCL)</td> </tr> <tr> <td class="indent2"> <ul> <li>Erythrodermic mycosis fungoides/Sézary syndrome</li> </ul> </td> <td>ECP</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Non-erythrodermic mycoses fungoides</li> </ul> </td> <td>ECP</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" rowspan="2">Dilated cardiomyopathy, idiopathic, NYHA II-IV</td> <td>IA</td> <td>II</td> <td>1B</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Erythrocytosis</td> </tr> <tr> <td class="indent2"> <ul> <li>Polycythemia vera</li> </ul> </td> <td>Erythrocytapheresis</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Secondary erythrocytosis</li> </ul> </td> <td>Erythrocytapheresis</td> <td>III</td> <td>1C</td> </tr> <tr> <td class="indent1">Erythropoietic protoporphyria, liver disease</td> <td>TPE/RBC exchange</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Familial hypercholesterolemia</td> </tr> <tr> <td class="indent2"> <ul> <li>Homozygous individuals</li> </ul> </td> <td>LA</td> <td>I</td> <td>1A</td> </tr> <tr> <td class="indent2"> <ul> <li>Heterozygous individuals</li> </ul> </td> <td>LA</td> <td>II</td> <td>1A</td> </tr> <tr> <td class="indent2"> <ul> <li>All patients</li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent1" colspan="4">Focal segmental glomerulosclerosis (FSGS)</td> </tr> <tr> <td class="indent2"> <ul> <li>Recurrent in kidney transplant</li> </ul> </td> <td>TPE/IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>All types</li> </ul> </td> <td>LA</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Steroid resistant in native kidney</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Graft-versus-host disease (GVHD)</td> </tr> <tr> <td class="indent2"> <ul> <li>Acute</li> </ul> </td> <td>ECP</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Chronic</li> </ul> </td> <td>ECP</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent1">Hemophagocytic lymphocytosis (HLH)</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Heparin-induced thrombocytopenia and thrombosis</td> </tr> <tr> <td class="indent2"> <ul> <li>Pre-procedure</li> </ul> </td> <td>TPE/IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Refractory or with thrombosis</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Hereditary hemochromatosis</td> <td>Erythrocytapheresis</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent1">Hyperleukocytosis</td> <td>Leukocytapheresis</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">Hypertriglyceridemic pancreatitis</td> </tr> <tr> <td class="indent2"> <ul> <li>Severe</li> </ul> </td> <td>TPE/LA</td> <td>III</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Prevention of relapse</li> </ul> </td> <td>TPE/LA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Hyperviscosity in hypergammaglobulinemia</td> </tr> <tr> <td class="indent2"> <ul> <li>Symptomatic</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Prophylaxis for rituximab</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class="indent1" colspan="4">Idiopathic inflammatory myopathies</td> </tr> <tr> <td class="indent2"> <ul> <li>Anti-synthetase-syndrome</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Clinically amyopathic dermatomyositis</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Immune-mediated necrotizing myopathies</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">IgA nephropathy (Berger's disease)</td> </tr> <tr> <td class="indent2"> <ul> <li>Chronic progressive</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Crescentic</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1">Immune checkpoint inhibitors, immune-related adverse events</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Immune thrombocytopenia (ITP), refractory</td> <td>TPE/IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Inflammatory bowel disease</td> </tr> <tr> <td class="indent2"> <ul> <li>Ulcerative colitis</li> </ul> </td> <td>Adsorptive cytapheresis</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Crohn disease</li> </ul> </td> <td>Adsorptive cytapheresis/ECP</td> <td>III</td> <td>1B/2C</td> </tr> <tr> <td class="indent1">Lambert-Eaton myasthenic syndrome</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1">Lipoprotein(a) hyperlipoproteinemia, progressive atherosclerotic cardiovascular disease</td> <td>LA</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent1">Malaria, severe*</td> <td>RBC exchange</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">Multiple sclerosis</td> </tr> <tr> <td class="indent2"> <ul> <li>Acute attack/relapse</li> </ul> </td> <td>TPE/IA</td> <td>II</td> <td>1A/1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Chronic</li> </ul> </td> <td>TPE/IA</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">Myasthenia gravis</td> </tr> <tr> <td class="indent2"> <ul> <li>Acute, short-term treatment</li> </ul> </td> <td>TPE/DFPP/IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Long-term treatment</li> </ul> </td> <td>TPE/DFPP/IA</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent1">Myeloma cast nephropathy</td> <td>TPE</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent1">Nephrogenic systemic fibrosis</td> <td>ECP/TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Neuromyelitis optical spectrum disorders (NMOSD)</td> </tr> <tr> <td class="indent2"> <ul> <li>Acute attack/relapse</li> </ul> </td> <td>TPE/IA</td> <td>II</td> <td>1B/1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Maintenance</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1"><em>N</em>-methyl-D-aspartate receptor antibody encephalitis</td> <td>TPE/IA</td> <td>I</td> <td>1C</td> </tr> <tr> <td class="indent1" colspan="4">Overdose, envenomation, and/or poisoning</td> </tr> <tr> <td class="indent2"> <ul> <li>Mushroom poisoning</li> </ul> </td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Envenomation</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Other</li> </ul> </td> <td>TPE/RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Paraneoplastic autoimmune retinopathies</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Paraneoplastic neurologic syndromes</td> <td>TPE/IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Pediatric autoimmune neuropsychiatric disorders</td> </tr> <tr> <td class="indent2"> <ul> <li>Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS)/Pediatric acute-onset neuropsychiatric syndrome (PANS), exacerbation</li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Sydenham chorea, severe</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" rowspan="2">Pemphigus vulgaris, severe</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td>IA/ECP/DFPP</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Peripheral vascular diseases</td> <td>LA</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent1">Phytanic acid storage disease (Refsum disease)</td> <td>TPE/LA</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1">Post-transfusion purpura (PTP)</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Progressive multifocal leukoencephalopathy (PML) associated with natalizumab</td> <td>TPE</td> <td>III</td> <td>1C</td> </tr> <tr> <td class="indent1">Pruritus due to hepatobiliary disease, treatment resistant</td> <td>TPE</td> <td>III</td> <td>1C</td> </tr> <tr> <td class="indent1" rowspan="3">Psoriasis, disseminated pustular</td> <td>ECP</td> <td>III</td> <td>2B</td> </tr> <tr> <td>Adsorptive cytapheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Red blood cell alloimmunization, pregnancy complications</td> </tr> <tr> <td class="indent2"> <ul> <li>Hemolytic disease of the fetus and newborn</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>RhD alloimmunization prophylaxis after transfusion</li> </ul> </td> <td>RBC exchange</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class="indent1">Sepsis with multiorgan failure</td> <td>TPE</td> <td>III</td> <td>2A</td> </tr> <tr> <td class="indent1" colspan="4">Sickle cell disease</td> </tr> <tr> <td class="indent2"> <ul> <li>Acute stroke</li> </ul> </td> <td>RBC exchange</td> <td>I</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Acute chest syndrome, severe</li> </ul> </td> <td>RBC exchange</td> <td>II</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Other acute complications</li> </ul> </td> <td>RBC exchange/TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Stroke prophylaxis</li> </ul> </td> <td>RBC exchange</td> <td>I</td> <td>1A</td> </tr> <tr> <td class="indent2"> <ul> <li>Pregnancy</li> </ul> </td> <td>RBC exchange</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Recurrent vaso-occlusive pain</li> </ul> </td> <td>RBC exchange</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Preoperative management</li> </ul> </td> <td>RBC exchange</td> <td>III</td> <td>2A</td> </tr> <tr> <td class="indent1">Steroid-responsive encephalopathy associated with autoimmune thyroiditis (Hashimoto encephalopathy)</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1">Stiff-person syndrome</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Sudden sensorineural hearing loss</td> <td>LA/DFPP/TPE</td> <td>III</td> <td>2A</td> </tr> <tr> <td class="indent1">Systemic lupus erythematosus (SLE): Severe complications</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1" rowspan="2">Systemic sclerosis</td> <td>ECP</td> <td>III</td> <td>2A</td> </tr> <tr> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Thrombocytosis</td> </tr> <tr> <td class="indent2"> <ul> <li>Symptomatic</li> </ul> </td> <td>Thrombocytapheresis</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Prophylactic or secondary</li> </ul> </td> <td>Thrombocytapheresis</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Thrombotic microangiopathy</td> </tr> <tr> <td class="indent2"> <ul> <li>Coagulation-mediated, due to pathogenic variants in <em>THBD</em>, <em>DGKE</em>, or <em>PLG</em></li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Complement-mediated, due to factor H autoantibodies</li> </ul> </td> <td>TPE</td> <td>I</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Complement-mediated, due to pathogenic variants in complement regulatory genes</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Drug-associated: Ticlopidine<sup>¶</sup></li> </ul> </td> <td>TPE</td> <td>I</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Drug-associated: Clopidogrel</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Drug-associated: Gemcitabine</li> </ul> </td> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Drug-associated: Quinine</li> </ul> </td> <td>TPE</td> <td>IV</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Infection-associated, from Shiga toxin-producing <em>Escherichia coli</em> (STEC-HUS), severe</li> </ul> </td> <td>TPE/IA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Infection-associated, from <em>Streptococcus pneumoniae</em> (pHUS)</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Pregnancy associated, severe</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Pregnancy associated, extremely preterm preeclampsia, severe</li> </ul> </td> <td>TPE/LA</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Thrombotic thrombocytopenic purpura (TTP; immune, with ADAMTS13 deficiency)</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1A</td> </tr> <tr> <td class="indent2"> <ul> <li>Transplantation-associated</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Thyroid storm</td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent1">Toxic epidermal necrolysis (TEN), refractory</td> <td>TPE</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, heart</td> </tr> <tr> <td class="indent2"> <ul> <li>Cellular/recurrent rejection</li> </ul> </td> <td>ECP</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Rejection prophylaxis</li> </ul> </td> <td>ECP/TPE</td> <td>II</td> <td>2A/IC</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization</li> </ul> </td> <td>TPE</td> <td>II</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Antibody-mediated rejection</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, hematopoietic stem cell, ABO incompatible</td> </tr> <tr> <td class="indent2"> <ul> <li>Major ABO incompatible, hematopoietic cells obtained from bone marrow</li> </ul> </td> <td>TPE</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Major ABO incompatible, hematopoietic cells obtained by apheresis</li> </ul> </td> <td>TPE</td> <td>II</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Minor ABO incompatible, hematopoietic cells obtained by apheresis</li> </ul> </td> <td>RBC exchange</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Pure RBC aplasia</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Transplantation, hematopoietic stem cell, HLA desensitization</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, intestine</td> </tr> <tr> <td class="indent2"> <ul> <li>Antibody mediated rejection</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, kidney, ABO compatible</td> </tr> <tr> <td class="indent2"> <ul> <li>Antibody mediated rejection</li> </ul> </td> <td>TPE/IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization/prophylaxis, living donor</li> </ul> </td> <td>TPE/IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, kidney, ABO incompatible</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization, living donor</li> </ul> </td> <td>TPE/IA</td> <td>I</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Antibody-mediated rejection</li> </ul> </td> <td>TPE/IA</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, liver</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization, ABO incompatible, living donor</li> </ul> </td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization, ABO incompatible, deceased donor</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Antibody-mediated rejection</li> </ul> </td> <td>ECP/TPE</td> <td>III</td> <td>2B/2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Immune suppression withdrawal</li> </ul> </td> <td>ECP</td> <td>III</td> <td>2B</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization, ABO incompatible</li> </ul> </td> <td>ECP</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Transplantation, lung</td> </tr> <tr> <td class="indent2"> <ul> <li>Chronic allograft dysfunction</li> </ul> </td> <td>ECP</td> <td>II</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Bronchiolitis obliterans syndrome</li> </ul> </td> <td>ECP</td> <td>II</td> <td>1C</td> </tr> <tr> <td class="indent2"> <ul> <li>Antibody-mediated rejection/desensitization</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Desensitization</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Vaccine-induced thrombotic thrombocytopenia, refractory</td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Vasculitis, ANCA-associated</td> </tr> <tr> <td class="indent2"> <ul> <li>Microscopic polyangiitis</li> </ul> </td> <td>TPE</td> <td>III</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Granulomatosis with polyangiitis</li> </ul> </td> <td>TPE</td> <td>III</td> <td>1B</td> </tr> <tr> <td class="indent2"> <ul> <li>Eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss)</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Vasculitis, IgA (Henoch-Schönlein purpura)</td> </tr> <tr> <td class="indent2"> <ul> <li>Crescentic rapidly progressive glomerulonephritis (RPGN)</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Severe extrarenal manifestations</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1" colspan="4">Vasculitis, other</td> </tr> <tr> <td class="indent2"> <ul> <li>Hepatitis B polyarteritis nodosa</li> </ul> </td> <td>TPE</td> <td>II</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Kawasaki disease</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent2"> <ul> <li>Multisystem inflammatory syndrome in children (MIS-C)</li> </ul> </td> <td>TPE</td> <td>III</td> <td>2C</td> </tr> <tr> <td class="indent1">Voltage-gated potassium channel (VGKC) antibody-related disease</td> <td>TPE/IA</td> <td>II</td> <td>1B</td> </tr> <tr> <td class="indent1">Wilson disease, fulminant</td> <td>TPE</td> <td>I</td> <td>1C</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>Refer to UpToDate topics on individual conditions for specific treatment recommendations. Due to UpToDate styling and alphabetization, the order of diseases in this table may differ slightly from the original source publication.</p>
<strong>Category</strong>
<ul class="decimal_heading">
<li>Category I: Disorders for which apheresis is accepted as first-line therapy, either as a standalone treatment or in conjunction with other therapies.</li>
<li>Category II: Disorders for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other therapies.</li>
<li>Category III: Disorders for which the optimal role of apheresis therapy is not established.</li>
<li>Category IV: Disorders for which published evidence demonstrates or suggests apheresis to be ineffective or harmful.</li>
</ul>
<p class="extra_spacing_top"><strong>Evidence</strong></p>
<ul class="decimal_heading">
<li>Evidence grade 1: Strong recommendation.</li>
<li>Evidence grade 2: Weak recommendation.</li>
<li>Evidence quality A: High-quality evidence.</li>
<li>Evidence quality B: Moderate-quality evidence.</li>
<li>Evidence quality C: Low-quality or very low-quality evidence.</li>
</ul></div><div class="graphic_footnotes"><p>TPE: therapeutic plasma exchange; IA: immunoadsorption; TPE-HV: high-volume therapeutic plasma exchange; ECP: extracorporeal photopheresis; DFPP: double filtration plasmapheresis; NYHA: New York Heart Association; RBC: red blood cell; LA: lipoprotein apheresis; Ig: immunoglobulin; HLA: human leukocyte antigen.</p>
<p>* UpToDate authors do not use RBC exchange for severe malaria.</p>
¶ UpToDate authors consider this entity (thrombotic microangiopathy [TMA] in the setting of ticlopidine) to be immune thrombotic thrombocytopenic purpura (iTTP) rather than drug-induced TMA because the patients had severe ADAMTS13 deficiency.</div><div class="graphic_reference">From: Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher 2023; 38:77. <a href="https://onlinelibrary.wiley.com/doi/10.1002/jca.22043" target="_blank">https://onlinelibrary.wiley.com/doi/10.1002/jca.22043</a>. Copyright © 2023 Wiley Periodicals LLC. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#d4a4b1a6b9bda7a7bdbbbaa794a3bdb8b1adfab7bbb9"><span class="__cf_email__" data-cfemail="98e8fdeaf5f1ebebf1f7f6ebd8eff1f4fde1b6fbf7f5">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="https://onlinelibrary.wiley.com/" target="_blank">https://onlinelibrary.wiley.com/</a>).</div><div id="graphicVersion">Graphic 86468 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
